Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate response to either conventional treatment options or tumor necrosis factor ...
U.S. net product sales for the fourth quarter of 2025 were $126.6 million, compared to $73.5 million for the same period in 2024. For the full year 2025, U.S. net product sales were $410.5 million, ...
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology focused medical technology company advancing novel drug delivery technologies alongside standard-of-care ...
Integrated Biosciences, a biotechnology company integrating optogenetics, chemistry, and AI to discover small molecule ...
Second season results from the Phase 3 SMART trial were presented at the 9th RSVVW Conference and will be shared with the U.S ...
Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a ...
Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the ...
GOTHENBURG, SWEDEN / ACCESS Newswire / February 19, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - XVIVO ...
Net cash used in operating and investing activities was $23.3 million and $163.7 million for the fourth quarter and full year of 2025, respectively; quarter-end cash and restricted cash position was ...
The Cancer/Oncology Drugs Market represents one of the most dynamic and innovation-driven sectors within the global ...
UPPSALA, SE / ACCESS Newswire / February 19, 2026 / Senzime AB (publ) (STO:SEZI)(OTCQX:SNZZF) today announced the launch of ...
The Precision Medicine Market represents a transformative shift in global healthcare, focusing on tailoring medical treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results